Product Description
Bromfenac ophthalmic is used to treat eye swelling and redness (inflammation) and pain that can occur after cataract surgery. Bromfenac ophthalmic is in a class of medications called nonsteroidal anti-inflammatory drugs (NSAIDs). It works by stopping the release of certain natural substances that cause pain and swelling. (Sourced from: https://medlineplus.gov/druginfo/meds/a611018.html)
Mechanisms of Action: COX1 Inhibitor,COX2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Topical,Ocular,Ophthalmic
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Austria | Bangladesh | Belgium | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hungary | Iceland | India | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lithuania | Mexico | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | Thailand | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: Pain Unspecified | Pain, Postoperative | Inflammation | Cataract | Pain Unspecified | Pain, Postoperative | Inflammation | Cataract
Known Adverse Events: Eye Pain | Pain Unspecified | Photophobia | Inflammation | Hypertension | Headache | Iritis
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|